Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2016 Dec 5;6:38262. doi: 10.1038/srep38262

Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism—The Young Finns Study

Emma Raitoharju 1,a, Ilkka Seppälä 1, Leo-Pekka Lyytikäinen 1, Jorma Viikari 2, Mika Ala-Korpela 3,4,5, Pasi Soininen 3,4, Antti J Kangas 3, Melanie Waldenberger 6, Norman Klopp 7,8, Thomas Illig 6,7,8, Jaana Leiviskä 9, Britt-Marie Loo 9, Niku Oksala 1,10, Mika Kähönen 11, Nina Hutri-Kähönen 12, Reijo Laaksonen 1, Olli Raitakari 13,14, Terho Lehtimäki 1
PMCID: PMC5137183  PMID: 27917915

Abstract

MicroRNAs are involved in disease development and may be utilized as biomarkers. We investigated the association of blood miRNA levels and a) fatty liver (FL), b) lipoprotein and lipid pathways involved in liver lipid accumulation and c) levels of predicted mRNA targets in general population based cohort. Blood microRNA profiling (TaqMan OpenArray), genome-wide gene expression arrays and nuclear magnetic resonance metabolomics were performed for Young Finns Study participants aged 34–49 years (n = 871). Liver fat status was assessed ultrasonographically. Levels of hsa-miR-122-5p and -885-5p were up-regulated in individuals with FL (fold change (FC) = 1.55, p = 1.36 * 10−14 and FC = 1.25, p = 4.86 * 10−4, respectively). In regression model adjusted with age, sex and BMI, hsa-miR-122-5p and -885-5p predicted FL (OR = 2.07, p = 1.29 * 10−8 and OR = 1.41, p = 0.002, respectively). Together hsa-miR-122-5p and -885-5p slightly improved the detection of FL beyond established risk factors. These miRNAs may be associated with FL formation through the regulation of lipoprotein metabolism as hsa-miR-122-5p levels associated with small VLDL, IDL, and large LDL lipoprotein subclass components, while hsa-miR-885-5p levels associated inversely with XL HDL cholesterol levels. Hsa-miR-885-5p levels correlated inversely with oxysterol-binding protein 2 (OSBPL2) expression (r = −0.143, p = 1.00 * 10−4) and suppressing the expression of this lipid receptor and sterol transporter could link hsa-miR-885-5p with HDL cholesterol levels.

Fatty liver (FL) is characterized by the accumulation of triacylglycerol-rich lipid droplets in hepatocytes (liver fat >5–10% of liver weight). The primary causes leading to hepatocellular lipid accumulation are not yet well understood, but they are thought to include alterations in the hepatic lipid uptake, synthesis, degradation, and secretion1. FL is the first stage of a continuum from benign, simple steatosis to steatohepatitis, fibrosis, cirrhosis, and even hepatocellular carcinoma2. Non-alcoholic FL disease (NAFLD) is defined as FL without evidence of excessive alcohol intake or other causes of steatosis2 and it has histological and pathological similarities with alcoholic liver disease (ALD)3. NAFLD is common in Western and Asian populations with a prevalence of 20–30% in the general population and 70–90% among the obese and diabetics4. It is also frequently associated with obesity, type 2 diabetes, and hyperlipidemia4. Individuals with ALD have been shown to be as metabolically unhealthy as subjects with NAFLD, and it is highly possible that ALD and NAFLD coexist5. In our population based Young Finns Study (YFS) sample, we have recently observed that alcohol consumption was significantly associated with the prevalence of FL only in normal-weight individuals, whereas in overweight or obese subjects the most significant correlates of FL were body mass index (BMI) and triglycerides6. Majority of the individuals with FL in YFS (ages 34–49 years) are men (74.1%). This is to be expected, as even though overall prevalence of NAFLD has been shown to be similar between the sexes, men reach their peak prevalence of NAFLD in their forties, whilst in women the prevalence of NAFLD is still increasing and reaches its peak in their sixth decade7. Although women are known to develop ALD with lesser alcohol consumption, men in YFS consume considerable more alcohol than the women8.

MicroRNAs (miRNAs, miRs) are small non-coding RNAs that primarily regulate gene expression by binding to target mRNAs and interfering with their translation9. MicroRNAs are transcribed from DNA to primary transcripts, which are then cleaved to shorter hairpin structures, exported to cytoplasm, and further processed to form mature one-stranded miRNAs. In most cases, miRNAs repress their targets by interaction with the 3′UTR of the target mRNA, inducing a detectable change in the mRNA levels10. MicroRNAs can also be transported between cells and tissues via circulation. Membrane-free miRNAs stabilized by proteins11,12 and miRNAs associated with lipid vesicles can be found in blood. Circulating miRNAs have also been found in high-density lipoproteins (HDL)13,14. Circulating miRNAs have been shown to participate in cell-to-cell communication15, potentially contributing to disease progression. Humans are predicted to have 2,588 mature microRNAs (mirBase, release 21) that can control several genes, and individual mRNAs can be bound by several miRNAs—miRNAs can thus establish wide regulatory networks affecting several metabolic processes.

The development of FL has been shown to alter the miRNA profiles in the liver16,17, serum18,19,20, and exosomes21. MicroRNAs have also been shown to affect the regulation of cholesterol metabolism22, liver inflammation23, hepatic fibrosis24, and the development of hepatocellular carcinoma25, all associated with NAFLD and ALD26,27. Even a serum miRNA expression panel consisting of hsa-miR-122-5p, -1290, -27b-3p, and -192-5p has been suggested for clinical NAFLD diagnostics18. Studies have shown increased levels of circulatory miR-122 in liver diseases with different etiologies18,20,23,28,29,30,31, indicating that it may be a potential marker for liver injury. In addition, for example the circulatory miRNAs related to inflammation, such as miR-21, -34a, -45128 and -155 have been associated to NAFLD (reviewed in refs 32 and 33). Still, many of the studies of miRNAs in FL disease have been performed with animal models. So far, miRNA profiling in humans has been done in small selected groups, and the larger studies have focused only on few specific preselected miRNAs18,19,20,21,23,28,30,34. These studies have also been performed in non-population based cohorts, and thus cannot be directly applied to general population. Therefore, wider miRNA profiling analyses with an adequate sample size and population based sampling are needed. The YFS is well-suited for this profiling, as the study participants have been extensively characterized and the population has a very low prevalence of viral hepatitis: according to the Finnish Red Cross, the prevalence of hepatitis B and C was 0.03% and 0.05%, respectively, among Finnish blood donors5.

The aims of the current study were to (i) compare blood miRNA levels between individuals with or without FL in a large population-based study cohort, (ii) investigate the association of discovered miRNAs and liver enzyme levels and explore the predictive ability of these miRNAs to detect FL over established risk factors, (iii) test the hypothesis that these miRNAs might be involved in the regulation of lipoprotein and lipid pathways connected to liver lipid accumulation by studying the association between dysregulated miRNAs and nuclear magnetic resonance (NMR) metabolomics and other characteristic previously associated with a metabolic dysfunction, (iv) further explore the mode of function of the miRNAs by analyzing the connections of these FL associated miRNAs with their predicted mRNA targets using transcriptomics analyses from the same samples. The flow and summary of the study is described in Supplementary Figure 1.

Materials and Methods

The Young Finns Study

YFS is a multicenter follow-up study on cardiovascular risk from childhood to adulthood in Finland. The YFS was launched in 1980, when 3,596 children and adolescents (3–18 years old) participated in the baseline study35. The subjects were randomly selected from Finnish national registry among the chosen age groups and the five study districts. Thereafter, the subjects have been followed up (in 1986, 2001, 2007 and 2011) with several examinations including comprehensive risk factor assessments. The 30-year follow-up was performed in 2011, with 2,063 adults, aged 34–49 years, participating in the study. The examinations included physical measurements, blood tests, and questionnaires. Participants in the follow-up studies have been found to be more often women and older than those who dropped out, but no significant differences in risk factors have been found35. The present study has been approved by the 1st ethical committee of the Hospital District of Southwest Finland on September 21st, 2010 and by local ethical committees. All study subjects gave an informed consent and the study was conducted according to the principles of the Declaration of Helsinki. YFS samples for miRNA analysis (n = 992) were selected independently form liver status from individuals having the most comprehensive data on risk factor, metabonomic, transcriptomics, genome wide genotyping and other phenotyping in the follow-up studies performed in 1986, 2001, 2007 and 2011. After quality control, study population comprises of 871 individuals with successful miRNA profiling (demographics in Table 1).

Table 1. Demographics of the subjects of Young Finns Study population with successful miRNA profiling.

  All subjects NL FLAll FLM FLC
Number of subjects 871 724 147 119 28
Age, years 42.4 (4.8) 42.1 (4.9) 43.6 (4.4) 43.5 (4.5) 44.3 (4.0)
Men, (%) 45.4 39.5 74.1 75.6 67.9
Total cholesterol, mmol/l 5.1 (0.9) 5.1 (0.9) 5.4 (1.0) 5.5 (1.0) 5.1 (1.1)
HDL cholesterol, mmol/l 1.3 (0.3) 1.4 (0.3) 1.2 (0.3) 1.2 (0.3) 1.1 (0.3)
LDL cholesterol, mmol/l 3.3 (0.8) 3.2 (0.8) 3.4 (0.9) 3.5 (1.0) 3.1 (0.9)
Triglycerides, mmol/l 1.2 (0.7) 1.1 (0.6) 1.8 (1.0) 1.8 (1.0) 1.8 (0.9)
Type 2 diabetes, (%) 1.7 1.2 10.9 9.2 17.9
Blood glucose, mmol/l 5.4 (0.9) 5.3 (0.8) 5.8 (1.0) 5.7 (1.0) 6.0 (1.1)
HbA1c, % 5.5 (0.4) 5.4 (0.4) 5.7 (0.6) 5.7 (0.5) 6.0 (0.7)
HbA1c, mmol/mol 36.5 (4.6) 36.0 (3.9) 39.1 (6.5) 38.5 (6.0) 41.8 (7.9)
Hypertension, (%) 8.2 5.4 21.8 17.6 39.3
Systolic BP, mmHg 119.1 (13.9) 117.3 (13.3) 127.7 (13.1) 127.0 (13.2) 130.8 (12.3)
Diastolic BP, mmHg 75.1 (10.5) 73.6 (9.9) 82.1 (10.4) 81.6 (10.8) 84.2 (8.2)
Body mass index, kg/m2 26.4 (4.9) 25.6 (4.3) 30.6 (5.8) 29.2 (4.0) 36.5 (8.2)
Alanine aminotransferase, U/l 16.9 (12.2) 14.3 (8.0) 29.6 (19.5) 28.0 (17.7) 36.4 (25.2)
Aspartate aminotransferase, U/l 22.2 (8.5) 21.0 (7.2) 28.2 (11.4) 27.4 (10.5) 31.3 (14.6)
γ-glutamyltransferase, U/l 30.6 (28.3) 25.6 (46.0) 55.6 (46.0) 54.8 (49.4) 58.8 (27.8)
Fatty liver index 3.8 (10.5) 1.9 (5.6) 13.3 (19.7) 8.5 (12.0) 33.3 (31.0)
Open in a new tab

Continuous variables are presented by means with standard deviations in parentheses.

Abbreviations: NL = normal liver, FL = fatty liver, FLM = mild fatty liver, FLC = clearly indentified fatty liver, FLAll = all subjects with fatty liver, HDL = high-density lipoprotein, LDL = low-density lipoprotein, HbA1c = glycosylated hemoglobin, BP = blood pressure.

Clinical and biochemical measurements

Weight and height were measured and BMI calculated as weight(kg)/(height(m))2. Waist circumference was measured to the nearest 0.1 cm. Blood pressure was measured with a random zero sphygmomanometer.

Venous blood samples were drawn from the right antecubital vein after an overnight fast. For blood count analysis, whole blood was anticoagulated with EDTA. Blood cell parameters were measured by flow cytometric particle counting (cells) and photometry (Hb) using Sysmex XE- 5000 and XT-2000i analyzers (Sysmex Corporation) with reagents provided by the manufacturer (Cellpack and Sulfolyser).

For the biochemical measurements, serum was separated, aliquoted and stored at −70 °C until analysis. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GT), glucose, cholesterol, and triglyceride concentrations were measured with ALT, AST, GT, Glucose, Cholesterol, and Triglycerides System Reagent, (Beckman Coulter Biomedical). Apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and C-reactive protein (CRP) were determined immunoturbidimetrically (ApoA1 and B assay reagent, Orion Diagnostica and CRP Latex reagent, Beckman Coulter Biomedical). The serum triglyceride concentration was assayed using the enzymatic glycerol kinase–glycerol phosphate oxidase method (Beckman Coulter Biomedical). Serum total cholesterol levels were measured by the enzymatic cholesterol esterase–cholesterol oxidase method (Beckman Coulter Biomedical). The same reagent was used for estimating HDL cholesterol levels after the precipitation of low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) with dextran sulfate- Mg2+. Serum glucose concentrations were determined by the enzymatic hexokinase method (Beckman Coulter Biomedical). All the above-mentioned assays were performed on an AU400 instrument (AU400, Olympus).

Glycated hemoglobin (HbA1c) fraction in whole blood was measured by an Abbott Architect ci8200 analyzer (Abbott Laboratories). The concentration of total hemoglobin was first determined colorimetrically, after which the concentration of HbA1c was measured immunoturbidimetrically using the microparticle agglutination inhibition method (Fisher Diagnostics). These two concentrations were used to calculate the HbA1c percentage. All the above-mentioned methods besides ALT, AST, and GT quantifications were accredited by the Finnish Accreditation Service (FINAS).

NMR metabolomics

A high-throughput serum NMR metabolomics platform was used for absolute quantification of serum lipids and metabolites, including lipoprotein subclass distributions, fatty acids, and various small molecules such as amino acids and glycolysis precursors36,37 (Supplementary Table 1). The analyzed 14 lipoprotein subclasses were defined based on particle size. These detailed lipoprotein subclass measurements, together with standard total lipids and apolipoproteins, provide a good basis for studying the lipid- and lipoprotein-related metabolic pathways. The NMR-based metabolic profiling has previously been used in various epidemiological and genetic studies37, and details of the experimentation have been described36,37,38. Data was available from all the individuals with successful miRNA profiling.

Liver ultrasonography

Ultrasound imaging and evaluation of hepatic fat in hepatic ultrasound scan images (taken in 2011) of the liver was performed using a validated protocol39 and Sequoia 512 ultrasound mainframes (Acuson) with 4.0 MHz adult abdominal transducers. The diagnostic evaluation of hepatic steatosis was performed visually using a standard system by a highly trained sonographer according to liver-to-kidney contrast, parenchymal brightness, deep beam attenuation, and bright vessel walls40. According to these criteria, the presence of hepatic steatosis (=fatty liver, FLAll) was assessed and the participants were further classified into subjects with clearly identifiably fatty liver (FLC) or mild fatty liver (FLM), and normal liver (NL).

RNA isolation and quality control

Whole blood (2.5 ml) was collected into PaXgene Blood RNA Tubes (PreAnalytix). The tubes were inverted 8–10 times then stored at room temperature for at least 2 hours. The tubes were frozen (−80 °C) and thawed overnight before RNA isolation (both miRNA and total RNA) with a PAXgene Blood microRNA Kit (Qiagen) including the DNase Set using the QiaCube. The concentrations and purity of the RNA samples were evaluated spectrophotometrically (BioPhotomer, Eppendorf). The RNA isolation process was validated by analyzing the integrity of several RNAs with the RNA 6000 Nano Chip Kit (Agilent). The presence of the small RNA fraction was confirmed by the Agilent Small RNA Kit (Agilent).

MicroRNA expression profiling

MicroRNA expression profiling was performed with the TaqMan® OpenArray® MicroRNA Panel (Applied Biosystems) containing 758 microRNAs. Briefly, 100 ng of RNA was used to run both A and B pools of Megaplex (Applied biosystems) preamplification for cDNA synthesis. In the OpenArray Sample Loading Plate, 22.5 μl of each preamplified pool was mixed 1:1 with TaqMan OpenArray Real-Time PCR Master Mix. MicroRNA panels were loaded using the AccuFill System and run with the QuantStudio 12 K Flex (Applied Biosystems).

Primary data analysis was performed with Expression Suite Software version 1.0.1. As recommended by the manufactures of the miRNA panels, RNU6, RNU44, and RNU48 were used as housekeeping small RNAs. Assays with Amplification score >1 and Cq Confidence >0.7 were accepted. Ninety-five samples were excluded due to a low number of miRNAs expressed (≤200 miRNAs per sample), and in further analysis, 243 miRNAs that were expressed in at least 2/3 of the samples were included (number of miRNAs present in detectable levels in majority of the blood samples is well in line with previous similar analysis of blood tissue41). The RNA quality and functionality of the TaqMan OpenArray microRNA expression panels have been validated previously42. After quality control and removal of outlier miRNAs, profiling was successful on 871 samples. To correct for batch effects, the principal component analysis was performed for the miRNA expression data. The data was adjusted for 10 of the first 20 principal components from the principal component analysis.

Genome-wide expression analysis (transcriptomics)

The expression levels were analyzed with an Illumina HumanHT-12 version 4 Expression BeadChip (Illumina Inc.). Utilizing the same RNA sample for both mRNA and miRNA expression profiling, 200 ng of RNA was reverse-transcribed into cDNA and biotin-UTP-labeled using the Illumina TotalPrep RNA Amplification Kit (Ambion); 1,500 ng of cDNA was then hybridized to the Illumina HumanHT-12 v4 Expression BeadChip. The BeadChips were scanned with the Illumina iScan system. Raw illumina probe data was exported from Genomestudio and analyzed in R (http://www.r-project.org/) using the Bioconductor (http://www.bioconductor.org/) packages. The expression data was processed using nonparametric background correction, followed by quantile normalization with control and expression probes, using the neqc function in the limma package and log2 transformation. Data processing described in more detailed in ref. 43. The expression analysis was successful in 743 of the 871 samples with a miRNA expression profile.

Statistical analysis

MicroRNA expressions were compared over individuals with NL, FLM and FLC (using one-way ANOVA for normally distributed miRNAs). In order to take account of the multiple testing Bonferroni corrected p-values (pc-value) were calculated and pc-value < 0.05 (=p < 0.00021) was considered significant. For dysregulated miRNAs fold changes (FCs) were calculated for each individual sample in comparison to the average of all individuals with NL. FL index was calculated as previously described44 and the levels of discovered miRNAs were correlated with this index using Spearman’s rank-order correlation and independent association was evaluated with linear regression model adjusted with age and sex.

The independent predictors of fatty liver status (FLAll vs. NL and FLC vs. NL) were researched using stepwise Akaike information criterion (AIC) logistic regression. Three different models were used as follows: Model 1: FL status (FLAll/FLC vs. NL) predicted with discovered miRNAs only, (one by one forced in to the model); Model 2: age, sex and BMI added among explanatory variables of model 1; and fully adjusted Model 3 including all explanatory variables known to be associated with FL in YFS study6 i.e., age, sex, BMI, alcohol consumption, waist circumference, age, apoB levels, triglycerides, insulin levels, systolic blood pressure, smoking, and physical activity index, (excluding liver enzymes due to high correlation with studied miRNAs). Only independent predictors of liver status remained in the final model. Similar analysis were done separately for normal weight (BMI < 25) and overweight or obese individuals (BMI > 25) as the explanatory parameters associated to FL have been shown to differ in these subpopulations6 and also separately for men and women and individuals with or without excess of alcohol consumption (>1.67 standard drinks per day; corresponding to 20 g of pure ethanol). In stratified analysis, only models predicting FLAll vs NL were possible, due to low number of individuals with FLC.

The sensitivity and specificity of the discovered miRNAs to detect individuals with FLAll or FLC was analyzed by the receiver operator curve (ROC) analysis and areas under curve (AUC) were compared between miRNAs and the liver enzymes ALT, AST and GT. To evaluate the incremental predictive value of miRNA levels in comparison to parameters known to be associated with FL in YFS participants6 (liver enzymes, sex, BMI, waist circumference, age, apoB levels, triglycerides, insulin levels, systolic blood pressure, smoking, alcohol consumption, and physical activity index), a continuous net classification improvement (NRI) was calculated using reclassification function in the PredictABEL R package. Only parameters with independent association to liver status were included in the model (ALT, GT, waist circumference, insulin levels and systolic blood pressure). All continuous variables were inverse-normalized. A p-value < 0.05 for continuous NRI was considered significant.

The correlation between miRNAs and metabolite levels as well as physiological features previously associated with metabolic dysfunction (list of metabolites and other characteristics shown in Supplementary Table 1) was analyzed using Spearman rank-order correlation. The independent predictors value of the FL associated miRNAs was analyzed by applying the stepwise AIC regression model including FL associated miRNAs (one by one forced into model) and sex, age, BMI, and liver status as explanatory variables when analyzing liver enzymes, and also with ALT, AST and GT when analyzing other phenotypes. All continuous variables were inverse-normalized, and individuals with ALT, AST or GT levels over the Finnish reference ranges were discarded from the analysis when other phenotypes were used as an dependent variable in the model.

The predicted mRNA target expressions were included in the analysis if they were recognized as a target of the miRNA of interest by at least two target prediction programs in miRGator v.3.045. Spearman’s rank-order correlations between the FCs of the miRNAs of interest and the expression their targets mRNA in transcriptomics analysis with a p < 0.05 are reported. An independent association was assessed with a same model as with metabolites. The pathways enriched by the down-regulated (p < 0.05) predicted target of these microRNAs were discovered by computing overlaps in a molecular signature database (http://www.broadinstitute.org/gsea/msigdb/annotate.jsp).

Results

Differences in blood levels of hsa-miR-122-5p and hsa-miR-885-5p between individuals with and without FL

One-way ANOVA over liver fat status groups (NL, FLM and FLC) showed a significant increasing trend for the levels of hsa-miR-122-5p (assay number 002245, successfully profiled form 703 individuals, p = 7.89 * 10−18, Bonferroni corrected pc = 1.92 * 10−15) and hsa-miR-885-5p (assay number 002296, successfully profiled form 868 individuals, p = 1.06 * 10−06, pc = 2.58 * 10−04). In comparison to individuals with NL, the expression of hsa-miR-122-5p was up-regulated in individuals with either FLM (FC = 1.45, p = 5.52 * 10−11) or FLC (FC = 1.97, p = 4.17 * 10−11) (Fig. 1A). Similarly, the expression of hsa-miR-885-5p was up-regulated in individuals with FLM (FC = 1.18, p = 3.80 * 10−4) and in those with FLC (FC = 1.55, p = 4.30 * 10−5) when compared to those with NL (Fig. 1B). Both, hsa-miR-122-5p and -885-5p were also up-regulated when comparing individuals with FLAll to individuals with NL (FC = 1.55, p = 1.36 * 10−14 and FC = 1.25, p = 4.86 * 10−4, respectively). These miRNAs were also associated with a FL, when analyzing separately in individuals with and without excess alcohol consumption (Supplementary Figure 2, One-way ANOVA over liver fat status groups; hsa-miR-122-5p p = 0.0001 and p = 3.10 * 10−12, respectively and hsa-miR-885-5p p = 0.005 and p = 0.007, respectively) to represent ALD and NAFLD.

Figure 1.

Figure 1

Open in a new tab

Blood levels of hsa-miR-122-5p (A) and hsa-miR-885-5p (B) in individuals without fatty liver (NL), or with mild (FLM) or clearly indentified fatty liver (FLC). Abbreviations: ANOVA = Analysis of variance, SE = standard error.

There were sex*miRNA interaction with hsa-miR-122-5p and hsa-miR-885-5 in respect to presence of FLAll (p = 2.69 * 10−4 and 0.046, respectively). In men the association of hsa-miR-122-5p levels with FL status (NL vs. FLM vs. FLC) was in parallel with women but statistically stronger (p = 1.72 * 10−12 for trend) than in women (p = 0.001). In similar analysis for hsa-miR-885-5p levels, the differences over liver status groups was seen only in men (p = 0.001 for men and p = 0.121 for women). Hsa-miR-122-5p and 885-5p correlated with FL index (r = 0.281, p = 3.54 * 10−14 and r = 0.105, p = 0.002, respectively). In linear regression model including age, sex and miRNA, hsa-miR-122-5p remained a significant independent predictor of FL index (p = 4.16 * 10−11, β = 0.227, 95% CI = 0.161–0.294 SD change in FL index per one SD increase of miRNA levels).

Hsa-miR-122-5p and -885-5p as predictors of fatty liver

In stepwise logistic regression model adjusted with age, sex and BMI hsa-miR-122-5p significantly predicted the existence of FLAll (OR = 2.07, 95% CI = 1.62–2.68, p = 1.29 * 10−8) and the effect of hsa-miR-122-5p remained significant also in the fully adjusted model (OR = 1.78 95% CI = 1.35–2.38, p = 6.84 * 10−5) (Table 2). In stratified analysis, with normal weight individuals (BMI ≤ 25) or overweigh and obese individuals (BMI > 25) the corresponding ORs were 3.1 (95% CI = 1.54–7.0, p = 0.003) and 1.57 (95% CI = 1.17–2.13, p = 0.003), respectively (supplementary Table 2). Similar ORs could also be seen when analyzing women and men separately (OR = 2.02, 95% CI = 1.20–3.56, p = 0.010 and OR = 1.77, 95% CI = 1.26–2.51, p = 0.001, respectively) and in moderate (<20 g alcohol per day) and excess alcohol users (≥20 g alcohol per day) (OR = 1.75, 95% CI = 1.28–2.44, p = 0.001 and OR = 2.03, 95% CI = 1.02–4.59, p = 0.059, respectively) (Supplementary Table 2).

Table 2. Logistic regression models (1–3) predicting fatty liver (FLAll or FLC) with hsa-miR-122-5p or -885-5p and known risk factors and biomarkers of FL.

Outcome MODEL 1
 MODEL 2
 MODEL 3
miR-122 miR-885 miR-122 miR-885 miR-122 miR-885
NL vs. FLAll
 n 703 871 701 868 632 781
 p-value 1.26 * 10−14 3.91 * 10−6 1.29 * 10−8 0.002 6.84 * 10−5 0.131
 OR 2.44 1.55 2.07 1.41 1.78 1.23
 95% CI 1.96–3.09 1.29–1.86 1.62–2.68 1.13–1.77 1.35–2.38 0.94–1.60
NL vs. FLC
 n 600 752 598 749 545 681
 p-value 5.59 * 10−9 1.33 * 10−4 1.93 * 10−6 9.83 * 10−4 2.48 * 10−3 0.353
 OR 4.61 2.14 6.67 2.47 3.64 1.37
 95% CI 2.83–7.96 1.46–3.19 3.28–15.97 1.46–4.33 1.69–9.29 0.71–2.73
Open in a new tab

MODEL 1: *Stepwise logistic regression model predicting FL (either FLAll or FLC) with miR-122-5p or miR-885-5p (one by one forced into model).

MODEL 2: Model 1+ age, sex and BMI.

MODEL 3: Model 2+ alcohol consumption, waist circumference, apolipoprotein B levels, triglycerides, insulin levels, systolic blood pressure, smoking, and physical activity index. This model involves all the explanatory variables that have been previously associated with liver status in Young Finns Study [see ref. 6] excluding liver enzymes due to high correlation with studied miRNAs.

Abbreviations: NL = Normal liver, FL = fatty liver, FLAll = all subjects with fatty liver, FLC = clearly identified fatty liver, miR-122 = hsa-miR-122-5p, miR-885 = hsa-miR-885-5p.

Also hsa-miR-885-5p significantly predicted the existence of FLAll in stepwise logistic regression model adjusted with age, sex and BMI (OR = 1.41 95%CI = 1.13–1.77, p = 0.002). In the fully adjusted model (Model 3) hsa-miR-885-5p predicted FLAll when all other risk factors were added to the model (including alcohol consumption), but the addition of insulin levels abolished the significance of the predictive value of this miRNA (OR = 1.23 95%CI = 0.94–1.60, p = 0.131) (Table 2). In the sex, weight and alcohol usage stratified analysis, hsa-miR-885-5p was an independent predictor of FLAll in the model including age, BMI and sex (no included in the sex stratified analysis) but not in the fully adjusted model, with the exception of the group of subjects with excess alcohol usage where the results remained significant (OR = 2.08, 95%CI = 1.18–3.94, p = 0.016) (Supplementary Table 2).

Associations of hsa-miR-122-5p and -855-5p with serum liver enzymes

Hsa-miR-122-5p and 855-5p both correlated with the levels of ALT, AST and GT (pc < 3.05 * 10−6 for all). Also in stepwise linear regression models including age, sex, BMI and liver status, the individual FL associated miRNAs (hsa-miR-122-5p and -885-5p one by one) predicted significantly all liver enzyme levels (Table 3).

Table 3. Correlation and adjusted linear regressions between hsa-miR-122-5p and -885-5p and serum liver enzyme levels.

  Spearman correlation
 Linear regression model*
n p pc r n p ß (95% CI)
Hsa-miR-122-5p
 ALT 703 5.01 * 10−33 1.22 * 10−30 0.43 701 1.07 * 10−25 0.319 (0.262–0.376)
 AST 703 4.49 * 10−26 1.09 * 10−23 0.384 701 3.43 * 10−22 0.321 (0.258–0.384)
 GT 703 5.43 * 10−17 1.32 * 10−14 0.309 701 2.10 * 10−7 0.163 (0.102–0.224)
Hsa-miR-885-5p
 ALT 868 3.78 * 10−19 9.18 * 10−17 0.297 868 9.33 * 10−14 0.377 (0.149–0.252)
 AST 868 1.71 * 10−16 4.16 * 10−14 0.275 868 4.19 * 10−12 0.205 (0.148–0.262)
 GT 868 1.26 * 10−08 3.05 * 10−6 0.192 868 4.97 * 10−4 0.096 (0.042–0.150)
Open in a new tab

*Statistical model: Stepwise linear regression model predicting liver enzyme levels (one by one) with miR-122-5p or miR-885-5p (one by one forced into model), age, sex, BMI, and liver status. Abbreviations: ALT = Alanine aminotransferase, AST = Aspartate aminotransferase, GT = gamma-glutamyltransferase, r = correlation estimate, pc = Bonferroni corrected p-value. Betas (β) indicates the standard deviation (SD) change of the liver enzyme levels per increase of one SD of miRNA levels.

Improvement of fatty liver prediction by hsa-miR-122-5p and -855-5p over traditional fatty liver risk factors

When comparing the utility of FL associated miRNAs in identifying individuals FLC or with FLAll to commonly utilized liver enzyme levels (ALT, AST and GT), the AUC of the hsa-miR-122-5p levels from the was comparable to ALT and GT (Fig. 2A–C). Moreover, hsa-miR-122-5p outperformed AST when detecting individuals with FLC (Fig. 2A and C). In this ROC analysis when comparing AUCs of hsa-miR-885-5p levels to those of liver enzymes in detecting FLAll all liver enzymes performed better than hsa-miR-885-5p (Fig. 2B and C).

Figure 2.

Figure 2

Open in a new tab

Receiver operating characteristi curve (ROC) analysis of the clinical utility (sepecificity and sensitivity) of blood levels of hsa-miR-122-5p and -885-5p in comparison to the serum levels of liver enzymes when predicting individuals with FLC (A and C) or FLAll (B and C). Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, GT = gamma-glutamyltransferase, FLAll = all subjects with fatty liver, FLC = clearly identified fatty liver.

Together hsa-miR-122-5p and -885-5p slightly improved the detection of FLC beyond established risk factors alone (continuous NRI = 1.36, 95% CI = 1.06–1.67, p = 2.8 * 10−18) (Table 4). Also including these miRNAs to the model predicting individuals with FLAll showed minor, but significant NRI (NRI = 0.278, 95%CI = 0.077–0.480, p = 0.0067) (Table 4). In sex stratified analysis, hsa-miR-122-5p and -885-5p slightly improved the detection of FLAll beyond established risk factors alone in both men and women separately (continuous NRI = 0.445, 95% CI = 0.068–0.821, p = 0.021 for women and continuous NRI = 0.383, 95% CI = 0.142–0.624, p = 0.0019, for men) but not in the weight stratified analysis (Supplementary Table 3).

Table 4. Continuous net reclassification improvement (NRI) of risk stratification of fatty liver after adding hsa-miR-122-5p and hsa-885-5p to the different base models* including conventional risk factors.

Model/microRNAs AUC NRI (95% CI) p-value
Model 1 (predicting FLCvs. NL) 0.983 Reference Reference
+hsa-miR-122-5p 0.986 0.963 (0.570–1.356) 1.6 * 10−6
+hsa-miR-885-5p 0.983 0.139 (−0.296–0.575) 0.53
+hsa-miR-122-5p and hsa-miR-885-5p 0.987 1.363 (1.057–1.670) 2.8 * 10−18
Model 2 (predicting FLAll vs. NL) 0.897 Reference Reference
+hsa-miR-122-5p 0.898 0.125 (−0.080–0.329) 0.23
+hsa-miR-885-5p 0.897 0.055 (−0.1515–0.262) 1.00
+hsa-miR-122-5p and hsa-miR-885-5p 0.898 0.278 (0.077–0.480) 0.0067
Open in a new tab

*Statistical model: Stepwise models 1 and 2 consist of all variables associated with FL in the Young Finns Study [see ref. 6].

Variables with independent and significant prediction value were: Model 1: Alanine aminotransferase (ALT), gamma-glutamyltransferase (GT), waist circumference, insulin levels predicting individuals with FLC vs. NL (NL n = 524, FLC n = 21).

Model 2: ALT, GT, waist circumference, insulin levels, and systolic blood pressure predicting individuals with FLAll vs NL (NL n = 524, FLAll n = 108).

Abbreviations: AUC = area under curve, NL = normal liver, FL = fatty liver, FLAll = all subjects with FL, FLC = clearly identified fatty liver.

Hsa-miR-122-5p and -885-5p as predictors of serum lipoprotein subclass components involved in lipid and lipoprotein pathways

In metabonomics analysis, hsa-miR-122-5p and -885-5p levels correlated with several metabolites and physiological features associated with metabolic dysfunction (data not shown), but independent prediction value in linear regression model including sex, age, BMI, liver status, ALT, AST, GT and miRNA (miRNAs forced in the model one by one) existed only when predicting size and components of lipoprotein subclasses and apolipoprotein levels (Fig. 3, Supplementary Table 4). Hsa-miR-122-5p (n = 668) predicted small VLDL, IDL, and large LDL particle concentrations, their lipid component and cholesterol concentrations and apoB levels (Fig. 3). Hsa-miR-885-5p (n = 835) predicted significantly very large HDL subclass free cholesterol, cholesterol esters, total cholesterol, phospholipid and total lipid concentrations (Fig. 3. and Supplementary Table 4). The hsa-miR-122-5p also significantly predicted immunoturbidimetrically measured apoB levels (β = 0.092, 95%CI = 0.021–0.162, p = 0.011). Neither hsa-miR-122-5p nor -885-5p levels correlated significantly with leucocyte count (data not shown).

Figure 3. Associations of hsa-miR-122-5p and -885-5p with lipoprotein subclass particle size and lipid components as well apoliporoteins A1 and B.

Figure 3

Open in a new tab

Standard deviation (SD) increment in metabolite measure and 95% confidence intervals (95% CI) per one SD change of miRNA are presented. Statistically significant results are highlighted with a star. Associations have been analyzed with a stepwise linear regression model adjusted with age, sex, BMI, liver status, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltransferase (GT) and individuals with ALT, AST or GT levels over the Finnish reference ranges have been removed from the analysis. Abbreviations: XL = extra large, L = large, M = medium, S = small, XS = extra small, HDL = high-density lipoprotein, LDL = low-density lipoprotein, IDL = intermediate-density lipoprotein, VLDL = very-low-density lipoprotein.

Hsa-miR-122-5p and -855-5p as predictors of their in silico predicted target mRNA levels

Correlation and adjusted (age, sex, BMI, liver status and liver enzyme levels) linear regressions between hsa-miR-122-5p and -885-5p and in silico predicted mRNA target expression levels from transcriptomics analyses are shown in Table 5. Hsa-miR-885-5p levels correlated significantly with the levels of 48 predicted mRNA targets (Supplementary Table 5). The correlations with AHNAK nucleoprotein (AHNAK), trophinin (TRO) and oxysterol binding protein like 2 (OSBPL2) were significant after multiple testing correction (pc < 0.05 i.e. p < 0.00021). In linear regression adjusted for age, sex, BMI, liver status, ALT, AST and GT, hsa-miR-885-5p predicted inversely (indicating a possible direct miRNA-induced target gene expression reduction) with GABA(A) receptor-associated protein (GABARAP), OSBPL2, arylsulfatase A (ARSA), and radial spoke 3 homolog (Chlamydomonas) (RSPH3) (Table 5), OSBPL2 being the only mRNA with statistically significant negative Spearman correlation with hsa-miR-885-5p levels (after multiple testing correction), of which levels were independently predicted by hsa-miR-885-5p levels in the regression model.

Table 5. Correlation and adjusted linear regressions between hsa-miR-122-5p and -885-5p and in silico predicted mRNA target expression levels from transcriptomics analysis.

Gene ID Accession ID Spearman correlation
 Linear regression model*
n p-value r n p-value β (CI(95%)
Hsa-miR-122-5p
 CS NM_004077.2 616 0.002 0.122 586 0.005 0.131 (0.041–0.222)
 ARSB NM_000046.2 616 0.038 0.084 586 0.005 0.118 (0.036–0.201)
 TRAK1 NM_014965.2 616 0.002 0.123 586 0.009 0.122 (0.031–0.213)
 PTP4A1 NM_003463.3 616 0.004 0.114 586 0.011 0.113 (0.026–0.200)
 CCDC69 NM_015621.2 616 0.032 0.087 586 0.013 0.106 (0.023–0.190)
 TRAK1 NM_001042646.1 616 0.032 0.086 586 0.013 0.109 (0.023–0.194)
 CCDC43 NM_144609.1 616 0.032 0.086 586 0.014 0.102 (0.021–0.182)
 BCL2L2 NM_004050.2 616 0.029 0.088 586 0.014 0.114 (0.023–0.205)
 LCMT1 NM_016309.2 616 0.033 0.086 586 0.014 0.105 (0.021–0.188)
 EIF1AX NM_001412.3 616 0.014 −0.099 586 0.016 −0.111 (−0.201–−0.021)
 LAMC1 NM_002293.2 616 0.016 0.097 586 0.018 0.103 (0.018–0.188)
 SHCBP1 NM_024745.2 616 0.047 0.080 586 0.020 0.105 (0.017–0.194)
 SORT1 NM_002959.4 616 0.020 0.094 586 0.031 0.099 (0.009–0.189)
 CANX NM_001024649.1 616 0.003 0.118 586 0.037 0.097 (0.006–0.188)
 ZC3H10 NM_032786.1 616 0.033 −0.086 586 0.039 −0.090 (−0.175–−0.005)
 PPAPDC1B NM_032483.2 616 0.044 0.081 586 0.041 0.096 (0.004–0.187)
 GALNT10 NM_198321.2 616 0.042 0.082 586 0.042 0.097 (0.004–0.191)
 SUSD1 NM_022486.3 616 0.001 0.138 586 0.042 0.085 (0.003–0.167)
 ATP5A1 NM_004046.4 616 0.044 0.081 586 0.049 0.092 (0.001–0.184)
Hsa-miR-885-5p
 GABARAP NM_007278.1 740 0.032 −0.079 712 0.002 −0.120 (−0.194–−0.046)
 ARSA NM_000487.3 740 0.022 −0.084 712 0.005 −0.111 (−0.188–−0.035)
 AHNAK NM_024060.2 740 3.2 * 10−5 0.152 712 0.013 0.094 (0.020–0.168)
 RSPH3 NM_031924.3 740 0.002 −0.111 712 0.014 −0.094 (−0.169–−0.019)
 OSBPL2 NM_144498.1 740 1.0 * 10−4 −0.143 712 0.015 −0.095 (−0.171–−0.019)
 UQCC NM_199487.1 740 0.001 0.126 712 0.015 0.095 (0.019–0.172)
 HNRNPL NM_001005335.1 740 0.032 0.079 712 0.018 0.091 (0.016–0.166)
 TRO NM_001039705.1 740 4.6 * 10−5 0.149 712 0.019 0.092 (0.015–0.169)
 FCRL6 NM_001004310.1 740 0.041 0.075 712 0.022 0.093 (0.014–0.172)
 APOL3 NM_030644.1 740 0.001 0.118 712 0.022 0.088 (0.013–0.164)
 PPP2R1A NM_014225.3 740 0.005 0.102 712 0.028 0.087 (0.010–0.165)
Open in a new tab

*Statistical model: In silico predicted gene target (gene ID) expression predicted with FL associated miRNAs (one by one forced in the model) adjusted with age, sex, BMI, liver status, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltransferase (GT). Note: Individuals with ALT, AST or GT levels over the Finnish reference ranges were removed from the analysis.

The majority of the 77 correlations (Spearman correlation p < 0.05) between hsa-miR-122-5p levels and its predicted target mRNA expressions levels were direct (Supplementary Table 6) and none were significant after multiple testing correction (pc < 0.05 i.e. p < 0.00021). In linear regression model adjusted with age, sex, BMI, liver status, ALT, AST and GT, hsa-miR-122-5p inversely predicted eukaryotic translation initiation factor 1A, the X-linked (EIF1AX) and zinc finger CCCH-type containing 10 (ZC3H10) expressions, indicating their possible direct miRNA-induced target gene expression reduction (Table 5). In pathway analysis, miRNA targets with negative association to hsa-miR-122-5p and/or -855-5p were not enriched in any specific pathways.

Discussion

We found that elevated blood levels of hsa-miR-122-5p and -885-5p were associated with ultrasonographically detected FL in individuals with and without excess alcohol consumption in a large, population-based cohort of adults. These miRNAs highly correlated with serum liver enzyme levels and FL index. In the prediction of FLC, the levels of hsa-miR-122-5p were comparable to most commonly used liver enzyme levels and both hsa-miR-122-5p and -885-5p together improved risk stratification beyond established risk factors. In the metabolomic analysis, hsa-miR-122-5p levels were found to independently predict apoB, small VLD, IDL, and large LDL component levels, while hsa-miR-885-5p levels were inversely associated with very large HDL total lipid, phospholipid and cholesterol content. Finally, the levels of hsa-miR-885-5p correlated inversely with its predicted target mRNA OSBPL2 expression, presenting a possible link between hsa-miR-885-5p and both HDL levels and it lipid content.

The association of hsa-miR-122-5p blood levels with FL, FL index and liver enzyme levels independently of age, sex, and BMI was shown here in a large clinically asymptomatic population. Levels of this miRNA remained as a significant predictor of FL when adjusting with known traditional risk factors of FL and the predictive value could be seen in normal weight and overweight individuals independently. This confirms the previous result where elevated miR-122 serum/plasma levels in individuals with NAFLD in comparison to those without has been detected small case-control profiling studies (n < 50)18,20,34 and two large expression analyses with selected miRNAs (n~400 each; 4–5 miRNAs quantified)18,28. Our study also extends the data applicability to general population. Hsa-miR-122-5p is almost solely expressed in the liver, and it is the most expressed miRNA in the liver, constituting approximately 70% of liver miRNA expression46. During the progression of NAFLD, liver miR-122 levels have been shown to be down-regulated in mice47,48 and humans16. There have also been conflicting results on the effects of alcohol consumption on miR-122 liver expression49,50, but it seems certain that the development of ALD also affects miR-122 expression in the human liver17. Even modest amount of alcohol consumption has been show to elevate serum miR-122 levels51. Pathological states in the liver [NAFDL18,28, ALD23 cirrhosis52, cancer29, toxicity53 and infection31] have all been shown to be associated with altered serum/plasma levels of miR-122. In support to our results associating hsa-miR-122-5p levels with liver enzyme levels, the serum levels of miR-122 have been previously shown to be associated with ALT and total cholesterol in hepatitis C patients receiving a nucleic acid-based miR-122 inhibitor54. Priola et al. also showed significant correlation between miR-122 and ALT, AST and GT and their results indicate that miR-122 may even regulate ALT activity34.

The increased levels of hsa-miR-885-5p were associated with FL. Levels of this miRNA remained an independent predictor of FL when adjusting with age, sex, BMI and most of the risk factors of FL, including alcohol consumption, but the significance was abolished when insulin levels were added to predicting model. Previous studies have indicated that hsa-miR-885-5p expression is relatively liver tissue enriched55 but also peripheral blood mononuclear cells have been thought to express this miRNA56, indicating possible function in liver and in blood stream. In line with our results, up-regulation of plasma miR-885-5p levels has been reported in paracetamol induced liver toxicity53. In contrast to a previous finding of increased levels of miR-885-5p in liver cirrhosis and hepatocellular carcinoma in a small case control study55, we observed an independent and direct association between miR-885-5p and ALT, AST and GT concentrations in our wide population-based sample. In addition, we found for the first time that hsa-miR-885-5p levels were inversely correlated with large HDL cholesterol independently of age, sex, BMI, measured liver enzyme levels and liver fat status.

Blood hsa-miR-122-5p levels were comparable to serum liver enzyme levels when identifying individuals with FL. Adding hsa-miR-122-5p and -885-5p to a model containing traditional risk factors and biomarkers of FL improved the risk stratification of FL. Although the improvement was statistically significant, it was minor and, unlike in the study by Tan et al.18 or Pirola et al.34 in more select populations, our results do not support blood miRNA levels having considerable novel clinical value in the diagnostics of FL in general population with no clinical symptoms of FL.

Our results of the metabolomic analysis showed that hsa-miR-122-5p levels had a direct association with small VLDL, IDL, large LDL subfractions, and apoB levels, indicating that hsa-miR-122-5p is connected with cholesterol levels in a viral hepatitis-free human population. These results are well supported by animal studies, where knock-out, knock-down, and overexpression studies on rodents and non-human primates have indicated that miR-122 expression modifies serum cholesterol and triglyceride levels by controlling cholesterol synthesis and VLDL secretion, and that suppressing miR-122 expression lowers LDL levels and increases HDL levels47,57,58,59. Hsa-miR-122-5p has also been detected in HDL and LDL particles14, and thus transport in lipoproteins may contribute to the direct associations observed between hsa-miR-122-5p and lipoprotein subfraction levels. In the present study, hsa-miR-122-5p levels did not correlate with the leucocyte count, suggesting that the measured concentrations do originate from serum. We did not find any predicted target mRNAs, which would have correlated negatively and significantly (after multiple testing correction) with hsa-miR-122-5p levels, indicating that this miRNA functions mainly in the liver.

In our transcriptomics analyses, we observed a significant inverse correlation between hsa-miR-885-5p and its target OSBPL2 expression. The OSBPL protein family has been shown to act as either lipid transporters or sterol sensors that control lipid metabolism by being involved in reverse cholesterol transport, vesicle transport, and cell signaling and by suppressing hepatic lipogenesis and VLDL production60. OSBPL2 has also been previously shown affect the metabolism of neutral lipids, possibly integrating the cellular metabolism of triglycerides with that of cholesterol61. Furthermore, OSBPL2 overexpression has been shown to be associated with increased cell efflux of cholesterol, apoA1, and phosphatidyl choline vesicles to serum62. Suppressing the expression of OSBPL2 may be hypothesized to be the biological pathway through which elevated hsa-miR-885-5p is associated with decreased levels of large HDL cholesterol.

A limitation of our study is that profiling miRNAs from peripheral blood poses a challenge in identifying the origin of the analyzed miRNAs, as blood contains miRNAs from circulatory cells but also vesicle- and protein-bound miRNA originating from various tissues. Whole blood was selected to enable gene-expression analysis from the same sample. Although clinical diagnosis of ADL or NAFLD was not available, we had detailed information about patients lifetime alcohol consumption, liver enzyme levels, disease status and ultrasonic assessment of FL. This data was used to separate subjects with FL without significant alcohol use and FL with alcohol use. The detection of fatty liver relies on ultrasonic assessment performed as a part of a scientific follow-up study, and liver biopsy (histology) was not available due to ethical reasons. According to the Finnish Red Cross, the prevalence of hepatitis B and C are 0.03% and 0.05%, respectively, among Finnish blood donors and even though we have excluded individuals with ALT, AST and GT levels over the Nordic reference ranges from transcriptomics and metabolomics analysis, we cannot exclude that some of the study subject may have had steatohepatitis, which could affect the these results. In addition, majority of individuals with FL in our population are men. Even though sex has been included in statistical analyses as covariate and sex stratified analyses were performed, possible features specific for FL in women could have been missed due to low number of women with FL. The results cannot therefore be directly generalized to older populations with equal amounts of women and men with FL. The strengths of this study are the large, well-phenotyped population-based cohort and the availability of comprehensive molecular phenotyping by serum NMR metabolomics, which enables detailed analysis of specific biological processes through which miRNAs may exert their effects. As this work is essentially descriptive, more research is needed to shed light on the mechanism how miRNAs are released into the blood and to validate the interaction of the discovered miRNAs and the their targets, for example In Vitro studies confirming the connection between hsa-miR-885-5p and OSBPL2 are needed.

In summary, we found that hsa-miR-122-5p and -885-5p are significantly up-regulated in individuals with ultrasonographically defined FL in a large Finnish population-based study cohort (YFS). The blood levels of hsa-miR-122-5p and -885-5p slightly improved FL prediction beyond established risk factors. In the metabolomics analysis, hsa-miR-122-5p levels were associated directly with levels of small VLDL, IDL, and large LDL components and hsa-miR-885-5p levels were associated inversely with extra-large HDL particle lipids and cholesterol levels. Furthermore, we found significant and inverse association between hsa-miR-885-5p and OSBPL2, a protein known to affect efflux of cholesterol.

Additional Information

How to cite this article: Raitoharju, E. et al. Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism—The Young Finns Study. Sci. Rep. 6, 38262; doi: 10.1038/srep38262 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Material

Supplementary Information
srep38262-s1.pdf (448.9KB, pdf)

Acknowledgments

The Young Finns Study has been financially supported by the Academy of Finland: grants 286284 (T.L.), 285902 (E.R.), 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; the Kuopio, Tampere, and Turku University Hospital Medical Funds (grant X51001 for T.L. and 9S054 for E.R.); the Juho Vainio Foundation; the Paavo Nurmi Foundation; the Finnish Foundation of Cardiovascular Research (T.L.); the Finnish Cultural Foundation; the Tampere Tuberculosis Foundation (T.L. and N.O.); the Emil Aaltonen Foundation (T.L. and N.O.); and the Yrjö Jahnsson Foundation (T.L. and N.O.). This work was also supported by the European Union 7th Framework Programme funding for the AtheroRemo project [201668], the Sigrid Juselius Foundation (MAK), the Strategic Research Funding from the University of Oulu (MAK), the Foundation of Clinical Chemistry, and the Orion-Farmos Research Foundation.

Footnotes

MAK, PS, and AJK are shareholders in Brainshake Ltd., a company offering NMR-based metabolite profiling.

Author Contributions E.R. acquired data, handled funding, performed statistical analyses, and wrote the manuscript. I.S. performed statistical analysis and reviewed the manuscript. L.-P.L. performed statistical analysis and reviewed the manuscript. J.V. participated in cohort collection and reviewed the manuscript. M.A.-K. acquired data and reviewed the manuscript. P.S. acquired data and reviewed the manuscript. A.J.K. acquired data and reviewed the manuscript. M.W. acquired data and reviewed the manuscript. N.K. acquired data. T.I. acquired data. J.L. acquired data and reviewed the manuscript. B.-M.L. acquired data and reviewed the manuscript. N.O. handled funding, contributed to the discussion and reviewed/edited the manuscript. M.K. participated in cohort collection and reviewed the manuscript. N.H.-K. participated in cohort collection and reviewed the manuscript. R.L. handled funding and supervision. O.R handled funding, participated in cohort collection, and reviewed the manuscript. T.L. handled funding and supervision, participated in cohort collection, and contributed to the discussion, in addition to reviewing/editing the manuscript.

References

  1. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221–1231 (2002). [DOI] [PubMed] [Google Scholar]
  2. Neuschwander-Tetri B. A. & Caldwell S. H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37, 1202–1219 (2003). [DOI] [PubMed] [Google Scholar]
  3. Sookoian S. & Pirola C. J. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. PLoS One 8, e58895 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Targher G., Day C. P. & Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341–1350 (2010). [DOI] [PubMed] [Google Scholar]
  5. Kotronen A. et al. Non-alcoholic and alcoholic fatty liver disease - two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey. BMC Public Health 10, 237-2458-10-237 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Suomela E. et al. Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study. Ann. Med. 47, 1–7 (2014). [DOI] [PubMed] [Google Scholar]
  7. Cheng H. Y. et al. Nonalcoholic Fatty Liver Disease: Prevalence, Influence on Age and Sex, and Relationship with Metabolic Syndrome and Insulin Resistance. Int J Gerontol. 7, 194–198 (2013). [Google Scholar]
  8. Kestila P. et al. Socioeconomic status, cardiovascular risk factors, and subclinical atherosclerosis in young adults: the cardiovascular risk in Young Finns Study. Arterioscler. Thromb. Vasc. Biol. 32, 815–821 (2012). [DOI] [PubMed] [Google Scholar]
  9. Silvestri P. et al. MicroRNAs and ischemic heart disease: towards a better comprehension of pathogenesis, new diagnostic tools and new therapeutic targets. Recent patents on cardiovascular drug discovery 4, 109–18 (2009). [DOI] [PubMed] [Google Scholar]
  10. Bartel D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Wang K., Zhang S., Weber J., Baxter D. & Galas D. J. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 38, 7248–7259 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hoefer I. E. et al. Novel methodologies for biomarker discovery in atherosclerosis. Eur. Heart J. 36, 2635–2642 (2015). [DOI] [PubMed] [Google Scholar]
  13. Kosaka N. et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 285, 17442–17452 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Vickers K. C., Palmisano B. T., Shoucri B. M., Shamburek R. D. & Remaley A. T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13, 423–433 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Valadi H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659 (2007). [DOI] [PubMed] [Google Scholar]
  16. Cheung O. et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48, 1810–1820 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Liu Y., Chen S. H., Jin X. & Li Y. M. Analysis of differentially expressed genes and microRNAs in alcoholic liver disease. Int. J. Mol. Med. 31, 547–554 (2013). [DOI] [PubMed] [Google Scholar]
  18. Tan Y., Ge G., Pan T., Wen D. & Gan J. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One 9, e105192 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Chen Y. P., Jin X., Xiang Z., Chen S. H. & Li Y. M. Circulating MicroRNAs as potential biomarkers for alcoholic steatohepatitis. Liver Int. 33, 1257–1265 (2013). [DOI] [PubMed] [Google Scholar]
  20. Cermelli S., Ruggieri A., Marrero J. A., Ioannou G. N. & Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6, e23937 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Murakami Y. et al. Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease. PLoS One 7, e48366 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Fernandez-Hernando C., Ramirez C. M., Goedeke L. & Suarez Y. MicroRNAs in metabolic disease. Arterioscler. Thromb. Vasc. Biol. 33, 178–185 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Bala S. et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 56, 194–1957 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Murakami Y. et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 6, e16081 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Murakami Y. et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25, 2537–2545 (2006). [DOI] [PubMed] [Google Scholar]
  26. Byrne C. D. & Targher G. NAFLD: a multisystem disease. J. Hepatol. 62, S47–64 (2015). [DOI] [PubMed] [Google Scholar]
  27. Altamirano J. & Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat. Rev. Gastroenterol. Hepatol. 8, 491–501 (2011). [DOI] [PubMed] [Google Scholar]
  28. Yamada H. et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin. Chim. Acta 424, 99–103 (2013). [DOI] [PubMed] [Google Scholar]
  29. Koberle V. et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur. J. Cancer 49, 3442–3449 (2013). [DOI] [PubMed] [Google Scholar]
  30. Celikbilek M. et al. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J. Hepatol. 6, 613–620 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Akamatsu S. et al. Differences in serum microRNA profiles in hepatitis B and C virus infection. J. Infect. 70, 273–287 (2015). [DOI] [PubMed] [Google Scholar]
  32. Szabo G. & Bala S. MicroRNAs in liver disease. Nat. Rev. Gastroenterol. Hepatol. 10, 542–552 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Gori M., Arciello M. & Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed. Res. Int. 2014, 741465 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Pirola C. J. et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 64, 800–812 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Raitakari O. T. et al. Cohort profile: the cardiovascular risk in Young Finns Study. International journal of epidemiology 37, 1220–6 (2008). [DOI] [PubMed] [Google Scholar]
  36. Soininen P. et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 134, 1781–1785 (2009). [DOI] [PubMed] [Google Scholar]
  37. Soininen P., Kangas A. J., Würtz P., Suna T. & Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ. Cardiovasc. Genet. 8, 192–206 (2015). [DOI] [PubMed] [Google Scholar]
  38. Inouye M. et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol. Syst. Biol. 6, 441 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Edens M. A. et al. Ultrasonography to quantify hepatic fat content: validation by 1H magnetic resonance spectroscopy. Obesity (Silver Spring) 17, 2239–2244 (2009). [DOI] [PubMed] [Google Scholar]
  40. Saverymuttu S. H., Joseph A. E. & Maxwell J. D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br. Med. J. (Clin. Res. Ed) 292, 13–15 (1986). [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Leidinger P., Backes C., Meder B., Meese E. & Keller A. The human miRNA repertoire of different blood compounds. BMC Genomics 15, 474-2164-15-474 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Raitoharju E. et al. Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome: The cardiovascular risk in Young Finns Study. Mol. Cell. Endocrinol. 391, 41–49 (2014). [DOI] [PubMed] [Google Scholar]
  43. Elovainio M. et al. Activated immune-inflammatory pathways are associated with long-standing depressive symptoms: Evidence from gene-set enrichment analyses in the Young Finns Study. J. Psychiatr. Res. 71, 120–125 (2015). [DOI] [PubMed] [Google Scholar]
  44. Bedogni G. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6, 33 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Cho S. et al. MiRGator v3.0: a microRNA portal for deep sequencing, expression profiling and mRNA targeting. Nucleic Acids Res. 41, D252–7 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Chang J. et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 1, 106–113 (2004). [DOI] [PubMed] [Google Scholar]
  47. Hsu S. H. et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Invest. 122, 2871–2883 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Tsai W. C. et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 122, 2884–2897 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. McDaniel K. et al. The functional role of microRNAs in alcoholic liver injury. J. Cell. Mol. Med. 18, 197–207 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Dippold R. P., Vadigepalli R., Gonye G. E., Patra B. & Hoek J. B. Chronic ethanol feeding alters miRNA expression dynamics during liver regeneration. Alcohol. Clin. Exp. Res. 37 Suppl 1, E59–69 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. McCrae J. C., Sharkey N., Webb D. J., Vliegenthart A. D. & Dear J. W. Ethanol consumption produces a small increase in circulating miR-122 in healthy individuals. Clin. Toxicol. (Phila) 54, 53–55 (2016). [DOI] [PubMed] [Google Scholar]
  52. Sohn W. et al. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp. Mol. Med. 47, e184 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Vliegenthart A. D. et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. Sci. Rep. 5, 15501 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Janssen H. L. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685–1694 (2013). [DOI] [PubMed] [Google Scholar]
  55. Gui J. et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin. Sci. (Lond) 120, 183–193 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Guan X. et al. A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer. FASEB J. 27, 1404–1412 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Elmen J. et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36, 1153–1162 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Elmen J. et al. LNA-mediated microRNA silencing in non-human primates. Nature 452, 896–899 (2008). [DOI] [PubMed] [Google Scholar]
  59. Esau C. et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell. Metab. 3, 87–98 (2006). [DOI] [PubMed] [Google Scholar]
  60. Zhou Y. et al. OSBP-related proteins (ORPs) in human adipose depots and cultured adipocytes: evidence for impacts on the adipocyte phenotype. PLoS One 7, e45352 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Hynynen R. et al. OSBP-related protein 2 is a sterol receptor on lipid droplets that regulates the metabolism of neutral lipids. J. Lipid Res. 50, 1305–1315 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Laitinen S. et al. ORP2, a homolog of oxysterol binding protein, regulates cellular cholesterol metabolism. J. Lipid Res. 43, 245–255 (2002). [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep38262-s1.pdf (448.9KB, pdf)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES